MULTEK
27.7.2018 14:47:06 CEST | Business Wire | Press release
Multek, a leading provider of Interconnect Solutions, today announced the completion of its previously announced acquisition by Suzhou Dongshan Precision Manufacturing Co. Ltd. (“DSBJ”) (SZSE: 002384), a diversified manufacturer headquartered in Suzhou, China. The transaction was announced in March 2018 by Multek’s outgoing parent company, Flex (NASDAQ: FLEX), in the form of a divestiture. The completion of this transaction follows the receipt of all necessary shareholder and regulatory approvals.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180727005287/en/
With the completion of its change in ownership, Multek becomes an indirect, wholly-owned subsidiary of DSBJ. Franck Lize, Chief Executive Officer of Multek, commented, “We are pleased to complete this transaction and very excited about our future as part of the DSBJ family of companies. Multek is now better positioned than ever to continue expanding capabilities and contribute to the combined company’s success, while supporting our customers’ future needs.”
"This transaction represents a new chapter and key milestone in DSBJ's 38-year history," said Yuan Yonggang, Chairman and President of DSBJ. "By acquiring Multek, we are creating a more powerful and global enterprise in the component technology space, with more than 25,000 employees, over five million square feet of manufacturing space, and adding over 300 active customers including the most respected brands in the US, Europe and Asia. With the merger complete, we aim to rapidly grow Multek by repeating the same successful recipe DSBJ used to significantly grow the sales of MFLEX, our last major acquisition in 2016, which was a similar-sized manufacturer in the same industry. In addition, Multek’s large and diversified account base -- spanning Smartphones, Wearables, IoT, Automotive, Medical, Communications Infrastructure, Computing, Consumer Electronics, Industrials and Instrumentation – presents excellent cross-fertilization opportunities for DSBJ’s existing companies and vice-versa."
Founded in 1978, Multek currently operates a 1.6 million square feet campus in Zhuhai, China, offering one-stop engineering and manufacturing services for rigid Printed Circuit Board (PCBs), flexible printed circuits (FPC), rigid-flex, and assembly. Multek’s plants and laboratories are equipped with state-of-the-art equipment.
About Multek
Multek, a wholly owned subsidiary of DSBJ (SZSE: 002384), is a leading value-add manufacturer of printed circuit board technologies offering a broad spectrum of PCB engineering and manufacturing expertise including high density interconnect, rigid, flexible, and rigid-flex printed circuit and assembly solutions. Serving customers in mobile, automotive, IoT, medical, wearable, telecommunications, computing, industrial and consumer electronics markets, Multek enables customers to take products to market quickly through early engineering, advanced technology new product introduction, and volume production. For more information, visit www.multek.com
About DSBJ
DSBJ, founded in 1980 in Suzhou, was successfully listed on the Shenzhen Stock Exchange (stock code: 002384) in 2010. DSBJ aims to be a leading technology provider of critical components in the intelligent world of IoT with one-stop R&D, manufacturing, sales and service for FPC, PCB, Rigid-Flex, LED packaging, Display Modules, and Telecom equipment, which are widely applied in the consumer electronics, telecommunications, and automotive industries. DSBJ achieved annual revenue of USD 2.37 billion in 2017.
View source version on businesswire.com: https://www.businesswire.com/news/home/20180727005287/en/
Contact:
Multek
Peter Yu, +852 2276-1633
peter.yu@multek.com
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom